{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:35:22Z","timestamp":1783478122431,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.mayocpiqo.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T16:16:08Z","timestamp":1604420168000},"page":"821-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Hypoparathyroidism: An Uncommon Complication Associated With Immune Checkpoint Inhibitor Therapy"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2923-6829","authenticated-orcid":false,"given":"Omar M.","family":"El Kawkgi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-0419","authenticated-orcid":false,"given":"Dingfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4500-8546","authenticated-orcid":false,"given":"Anupam","family":"Kotwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wermers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.mayocpiqo.2020.07.006_bib1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.mayocpiqo.2020.07.006_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy [published correction appears in Front Pharmacol. 2017;8:311]","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2020.07.006_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2020.07.006_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2020.07.006_bib5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2020.07.006_bib6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2020.07.006_bib7","doi-asserted-by":"crossref","first-page":"1039.e5","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"Am J Emerg Med"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2020.07.006_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40425-019-0528-x","article-title":"Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma","volume":"7","author":"Trinh","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2020.07.006_bib9","doi-asserted-by":"crossref","first-page":"e017703","DOI":"10.1136\/bmjopen-2017-017703","article-title":"Should total calcium be adjusted for albumin? A retrospective observational study of laboratory data from central Norway","volume":"8","author":"Lian","year":"2018","journal-title":"BMJ Open"},{"issue":"7656","key":"10.1016\/j.mayocpiqo.2020.07.006_bib10","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1136\/bmj.39582.589433.BE","article-title":"Diagnosis and management of hypocalcaemia [published correction appears in BMJ. 2008;336(7659)]","volume":"336","author":"Cooper","year":"2008","journal-title":"BMJ"},{"issue":"18","key":"10.1016\/j.mayocpiqo.2020.07.006_bib11","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMcp1800213","article-title":"Hypoparathyroidism","volume":"380","author":"Gafni","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2020.07.006_bib12","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1210\/jc.2015-3909","article-title":"Presentation of hypoparathyroidism: etiologies and clinical features","volume":"101","author":"Shoback","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2020.07.006_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2020.07.006_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients [published correction appears in Cancer Immunol Res. 2018;6(4):498-499]","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2020.07.006_bib15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2020.07.006_bib16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2020.07.006_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12967-018-1452-4","article-title":"Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors","volume":"16","author":"Gowen","year":"2018","journal-title":"J\u00a0Transl Med"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2020.07.006_bib18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ecl.2009.01.001","article-title":"Anti-parathyroid and anti-calcium sensing receptor antibodies in autoimmune hypoparathyroidism","volume":"38","author":"Brown","year":"2009","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2020.07.006_bib19","first-page":"119","article-title":"The incidence of parathyroid and other antibodies in the sera of patients with idiopathic hypoparathyroidism","volume":"1","author":"Blizzard","year":"1966","journal-title":"Clin Exp Immunol"},{"issue":"21","key":"10.1016\/j.mayocpiqo.2020.07.006_bib20","doi-asserted-by":"crossref","first-page":"8366","DOI":"10.1073\/pnas.83.21.8366","article-title":"Antibodies cytotoxic to bovine parathyroid cells in autoimmune hypoparathyroidism","volume":"83","author":"Brandi","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2020.07.006_bib21","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454820301326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454820301326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:09:38Z","timestamp":1762870178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454820301326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S2542454820301326"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2020.07.006","relation":{},"ISSN":["2542-4548"],"issn-type":[{"value":"2542-4548","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypoparathyroidism: An Uncommon Complication Associated With Immune Checkpoint Inhibitor Therapy","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}]}}